Share Price and Basic Stock Data
Last Updated: February 1, 2026, 10:22 pm
| PEG Ratio | 1.93 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fervent Synergies Ltd operates in the pharmaceutical sector, with a current stock price of ₹19.0 and a market capitalization of ₹94.8 Cr. The company reported total sales of ₹4.63 Cr for the fiscal year ending March 2023, which is a significant increase from ₹0.68 Cr in the previous fiscal year. Notably, the trailing twelve months (TTM) sales stood at ₹33.09 Cr, showcasing a recovery trajectory. Quarterly revenues demonstrated volatility; particularly, a surge was observed in December 2024, with sales reaching ₹26.33 Cr. The company’s revenue trends suggest a potential rebound, especially against a backdrop of low sales in preceding quarters, such as ₹0.23 Cr in September 2022 and ₹0.32 Cr in both June and September 2023. This fluctuation indicates the company’s current growth phase, albeit with challenges in maintaining consistent quarterly performance. Moreover, Fervent Synergies’ sales growth aligns with an industry trend where companies are capitalizing on increased healthcare spending and rising demand for pharmaceuticals, further solidifying its market position.
Profitability and Efficiency Metrics
The profitability metrics of Fervent Synergies Ltd reveal a mixed performance. The company reported a net profit of ₹0.23 Cr for FY 2023, which improved from a loss of ₹0.24 Cr the previous year. However, the operating profit margin (OPM) exhibited significant volatility, recording an OPM of 10.37% in FY 2023, a stark contrast to the negative OPM of -26.47% in FY 2022. For the latest quarter ending March 2025, the OPM stood at 9.21%, indicating a recovery trend. The interest coverage ratio (ICR) was remarkably high at 14,935.00x, underscoring the company’s ability to meet its interest obligations comfortably. However, the return on equity (ROE) and return on capital employed (ROCE) both stood at 7.47%, suggesting that while profitability is improving, it still lags behind the industry norms of higher returns typically seen in the sector. The company’s fluctuating profit figures and margins reflect the challenges of managing operational costs while scaling up revenue.
Balance Sheet Strength and Financial Ratios
Fervent Synergies Ltd exhibits a robust balance sheet characterized by negligible borrowings of ₹0.03 Cr and total assets amounting to ₹54.28 Cr as of September 2025. The reserves reported at ₹4.15 Cr indicate a solid foundation for future investments or contingencies. The current ratio is significantly high at 1166.31, reflecting excellent short-term liquidity, which is well above the typical industry benchmark of 1.5. Moreover, the price-to-book value (P/BV) ratio stands at 1.99x, aligning closely with sector averages, suggesting that shares are fairly valued relative to the company’s net assets. Furthermore, the enterprise value (EV) of ₹96.89 Cr indicates a growing market perception of the company’s value, particularly as it transitions out of a turbulent financial period. However, the substantial drop in reserves to ₹0.38 Cr in FY 2024 raises concerns about the sustainability of its growth and profitability.
Shareholding Pattern and Investor Confidence
Fervent Synergies Ltd has a concentrated shareholding structure, with promoters holding 74.75% of the company as of September 2025. This is a slight increase from 71.71% in March 2025, indicating a commitment from the founding members towards the company’s long-term vision. The public shareholding stood at 25.25%, which reflects moderate investor participation. The number of shareholders has gradually increased from 2,895 in December 2022 to 3,713 by September 2025, suggesting growing investor interest. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may indicate a lack of confidence or awareness in the broader investment community. This could pose a risk to stock liquidity and market perception, especially in volatile market conditions. Additionally, the high promoter stake could lead to potential governance concerns if not managed transparently, affecting investor sentiment.
Outlook, Risks, and Final Insight
The outlook for Fervent Synergies Ltd appears cautiously optimistic, driven by improving revenue trends and robust liquidity. However, the company faces significant risks, including operational inefficiencies reflected in fluctuating profit margins and the potential for continued volatility in quarterly sales. Additionally, the substantial drop in reserves in FY 2024 raises concerns over financial stability and sustainability. On the positive side, the high interest coverage ratio and strong promoter commitment suggest that the company is well-positioned to navigate challenges. Future growth will depend on maintaining operational efficiency and expanding market share in the increasingly competitive pharmaceutical sector. Should Fervent Synergies successfully leverage its strengths while mitigating risks, it could enhance shareholder value and establish a more consistent performance trajectory. Conversely, failure to address these challenges may hinder its potential in the long run.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 119 Cr. | 94.7 | 195/84.3 | 26.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,539 Cr. | 325 | 479/192 | 73.3 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.8 Cr. | 46.9 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 71.8 Cr. | 49.0 | 49.7/17.0 | 171 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,446.69 Cr | 1,087.86 | 46.54 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.23 | 3.27 | 0.89 | 0.32 | 0.32 | 8.83 | 14.85 | 0.34 | 0.39 | 26.33 | 5.40 | 0.68 | 0.68 |
| Expenses | 0.16 | 3.08 | 0.74 | 0.18 | 0.18 | 8.32 | 28.40 | 0.26 | 0.34 | 23.97 | 4.90 | 0.29 | 0.24 |
| Operating Profit | 0.07 | 0.19 | 0.15 | 0.14 | 0.14 | 0.51 | -13.55 | 0.08 | 0.05 | 2.36 | 0.50 | 0.39 | 0.44 |
| OPM % | 30.43% | 5.81% | 16.85% | 43.75% | 43.75% | 5.78% | -91.25% | 23.53% | 12.82% | 8.96% | 9.26% | 57.35% | 64.71% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 0.06 | 0.18 | 0.14 | 0.13 | 0.13 | 0.50 | -13.60 | 0.07 | 0.04 | 2.35 | 0.49 | 0.38 | 0.43 |
| Tax % | 33.33% | 27.78% | 100.00% | 23.08% | 23.08% | 26.00% | -1.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.05 | 0.14 | 0.00 | 0.10 | 0.09 | 0.37 | -13.41 | 0.07 | 0.04 | 2.35 | 0.50 | 0.38 | 0.43 |
| EPS in Rs | 0.02 | 0.05 | 0.00 | 0.03 | 0.03 | 0.12 | -4.47 | 0.02 | 0.01 | 0.54 | 0.11 | 0.08 | 0.09 |
Last Updated: December 27, 2025, 12:37 am
Below is a detailed analysis of the quarterly data for Fervent Synergies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.68 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.68 Cr..
- For Expenses, as of Sep 2025, the value is 0.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.29 Cr. (Jun 2025) to 0.24 Cr., marking a decrease of 0.05 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.44 Cr.. The value appears strong and on an upward trend. It has increased from 0.39 Cr. (Jun 2025) to 0.44 Cr., marking an increase of 0.05 Cr..
- For OPM %, as of Sep 2025, the value is 64.71%. The value appears strong and on an upward trend. It has increased from 57.35% (Jun 2025) to 64.71%, marking an increase of 7.36%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.43 Cr.. The value appears strong and on an upward trend. It has increased from 0.38 Cr. (Jun 2025) to 0.43 Cr., marking an increase of 0.05 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.43 Cr.. The value appears strong and on an upward trend. It has increased from 0.38 Cr. (Jun 2025) to 0.43 Cr., marking an increase of 0.05 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.09. The value appears strong and on an upward trend. It has increased from 0.08 (Jun 2025) to 0.09, marking an increase of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.63 | 3.51 | 3.67 | 39.15 | 5.51 | 16.67 | 7.35 | 2.21 | 0.68 | 4.63 | 24.31 | 32.46 | 33.09 |
| Expenses | 0.50 | 0.53 | 0.66 | 36.47 | 4.41 | 15.26 | 6.90 | 1.93 | 0.86 | 4.15 | 37.08 | 29.47 | 29.40 |
| Operating Profit | 2.13 | 2.98 | 3.01 | 2.68 | 1.10 | 1.41 | 0.45 | 0.28 | -0.18 | 0.48 | -12.77 | 2.99 | 3.69 |
| OPM % | 80.99% | 84.90% | 82.02% | 6.85% | 19.96% | 8.46% | 6.12% | 12.67% | -26.47% | 10.37% | -52.53% | 9.21% | 11.15% |
| Other Income | -0.04 | 0.00 | -0.07 | 0.83 | 0.06 | 0.41 | 0.03 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.06 | 0.04 | 0.01 | 0.19 | 0.01 | 0.07 | 0.15 | 0.01 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Depreciation | 0.05 | 0.05 | 0.05 | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | 1.98 | 2.89 | 2.88 | 3.31 | 1.14 | 1.74 | 0.31 | 0.23 | -0.20 | 0.44 | -12.85 | 2.95 | 3.65 |
| Tax % | 32.83% | 32.53% | 33.68% | 27.19% | 27.19% | 28.74% | 25.81% | 26.09% | 20.00% | 47.73% | 0.00% | 0.00% | |
| Net Profit | 1.33 | 1.95 | 1.91 | 2.41 | 0.83 | 1.23 | 0.24 | 0.17 | -0.24 | 0.23 | -12.84 | 2.95 | 3.66 |
| EPS in Rs | 0.53 | 0.65 | 0.64 | 0.80 | 0.28 | 0.41 | 0.08 | 0.06 | -0.08 | 0.08 | -4.28 | 0.67 | 0.82 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 46.62% | -2.05% | 26.18% | -65.56% | 48.19% | -80.49% | -29.17% | -241.18% | 195.83% | -5682.61% | 122.98% |
| Change in YoY Net Profit Growth (%) | 0.00% | -48.67% | 28.23% | -91.74% | 113.75% | -128.68% | 51.32% | -212.01% | 437.01% | -5878.44% | 5805.58% |
Fervent Synergies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 35% |
| 3 Years: | 263% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 65% |
| 3 Years: | 143% |
| TTM: | 125% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -5% |
| 3 Years: | -8% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 43.75 | 50.00 |
| Reserves | 3.49 | 6.44 | 8.34 | 10.75 | 11.80 | 12.78 | 12.58 | 13.04 | 12.99 | 13.22 | 0.38 | 4.89 | 4.15 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Other Liabilities | 0.72 | 1.02 | 1.02 | 1.49 | 0.39 | 0.71 | 0.82 | 0.70 | 0.14 | 0.23 | 0.14 | 0.14 | 0.10 |
| Total Liabilities | 29.21 | 37.46 | 39.36 | 42.24 | 42.19 | 43.49 | 43.40 | 43.74 | 43.13 | 43.45 | 30.52 | 48.78 | 54.28 |
| Fixed Assets | 0.49 | 0.48 | 0.45 | 1.94 | 3.57 | 17.60 | 17.79 | 17.76 | 16.10 | 16.06 | 7.52 | 7.48 | 7.47 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.00 | 0.00 | 2.16 | 0.00 | 0.97 | 0.72 | 0.28 | 0.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 27.72 | 36.98 | 36.75 | 40.30 | 37.65 | 25.17 | 25.33 | 25.41 | 27.03 | 27.39 | 23.00 | 41.30 | 46.81 |
| Total Assets | 29.21 | 37.46 | 39.36 | 42.24 | 42.19 | 43.49 | 43.40 | 43.74 | 43.13 | 43.45 | 30.52 | 48.78 | 54.28 |
Below is a detailed analysis of the balance sheet data for Fervent Synergies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 43.75 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 6.25 Cr..
- For Reserves, as of Sep 2025, the value is 4.15 Cr.. The value appears to be declining and may need further review. It has decreased from 4.89 Cr. (Mar 2025) to 4.15 Cr., marking a decrease of 0.74 Cr..
- For Borrowings, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.10 Cr.. The value appears to be improving (decreasing). It has decreased from 0.14 Cr. (Mar 2025) to 0.10 Cr., marking a decrease of 0.04 Cr..
- For Total Liabilities, as of Sep 2025, the value is 54.28 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 48.78 Cr. (Mar 2025) to 54.28 Cr., marking an increase of 5.50 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7.47 Cr.. The value appears to be declining and may need further review. It has decreased from 7.48 Cr. (Mar 2025) to 7.47 Cr., marking a decrease of 0.01 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 46.81 Cr.. The value appears strong and on an upward trend. It has increased from 41.30 Cr. (Mar 2025) to 46.81 Cr., marking an increase of 5.51 Cr..
- For Total Assets, as of Sep 2025, the value is 54.28 Cr.. The value appears strong and on an upward trend. It has increased from 48.78 Cr. (Mar 2025) to 54.28 Cr., marking an increase of 5.50 Cr..
Notably, the Reserves (4.15 Cr.) exceed the Borrowings (0.03 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 2.13 | 2.98 | 3.01 | 2.68 | 1.10 | 1.41 | 0.45 | 0.28 | -0.18 | 0.48 | -12.77 | 2.99 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 42.61 | 46.37 | 66.12 | 131.60 | 289.03 | 0.00 | 47.30 | 0.00 | 0.00 |
| Inventory Days | 12.16 | 0.00 | 0.00 | 80.66 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Days Payable | 0.00 | 0.00 | ||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 54.77 | 46.37 | 66.12 | 212.26 | 289.03 | 0.00 | 47.30 | 0.00 | 0.00 |
| Working Capital Days | 1,992.93 | 1,589.99 | 2,337.19 | 256.20 | 1,437.48 | 248.95 | 482.20 | 3,260.23 | 14,331.62 | 2,132.45 | 344.58 | 463.17 |
| ROCE % | 7.48% | 9.09% | 8.02% | 7.51% | 2.79% | 4.28% | 1.08% | 0.56% | -0.46% | 1.02% | -34.81% | 7.47% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.68 | -4.28 | 0.08 | -0.08 | 0.06 |
| Diluted EPS (Rs.) | 0.59 | -4.28 | 0.08 | -0.08 | 0.06 |
| Cash EPS (Rs.) | 0.68 | -4.27 | 0.09 | -0.06 | 0.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.12 | 10.13 | 14.40 | 14.33 | 14.35 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.12 | 10.13 | 14.40 | 14.33 | 14.35 |
| Revenue From Operations / Share (Rs.) | 7.42 | 8.10 | 1.54 | 0.22 | 0.73 |
| PBDIT / Share (Rs.) | 0.68 | -4.25 | 0.15 | -0.05 | 0.09 |
| PBIT / Share (Rs.) | 0.67 | -4.27 | 0.14 | -0.06 | 0.08 |
| PBT / Share (Rs.) | 0.67 | -4.28 | 0.14 | -0.06 | 0.07 |
| Net Profit / Share (Rs.) | 0.67 | -4.28 | 0.07 | -0.07 | 0.05 |
| PBDIT Margin (%) | 9.20 | -52.50 | 10.32 | -23.56 | 12.63 |
| PBIT Margin (%) | 9.08 | -52.67 | 9.45 | -29.04 | 10.98 |
| PBT Margin (%) | 9.08 | -52.84 | 9.45 | -29.11 | 10.60 |
| Net Profit Margin (%) | 9.09 | -52.82 | 4.97 | -34.94 | 7.89 |
| Return on Networth / Equity (%) | 6.07 | -42.27 | 0.53 | -0.55 | 0.40 |
| Return on Capital Employeed (%) | 6.05 | -42.00 | 1.01 | -0.45 | 0.56 |
| Return On Assets (%) | 6.05 | -42.08 | 0.52 | -0.55 | 0.39 |
| Asset Turnover Ratio (%) | 0.81 | 0.65 | 0.10 | 0.01 | 0.05 |
| Current Ratio (X) | 1166.31 | 795.38 | 205.92 | 781.01 | 43.67 |
| Quick Ratio (X) | 1166.31 | 795.38 | 205.92 | 781.01 | 43.67 |
| Interest Coverage Ratio (X) | 14935.00 | -304.63 | 2389.00 | -320.60 | 33.04 |
| Interest Coverage Ratio (Post Tax) (X) | 14769.00 | -305.48 | 1152.50 | -474.40 | 21.64 |
| Enterprise Value (Cr.) | 96.89 | 62.69 | 48.33 | 44.11 | 39.38 |
| EV / Net Operating Revenue (X) | 2.99 | 2.58 | 10.44 | 64.84 | 17.81 |
| EV / EBITDA (X) | 32.44 | -4.91 | 101.15 | -275.19 | 140.94 |
| MarketCap / Net Operating Revenue (X) | 2.99 | 2.58 | 10.48 | 65.27 | 20.11 |
| Price / BV (X) | 1.99 | 2.06 | 1.12 | 1.03 | 1.03 |
| Price / Net Operating Revenue (X) | 2.99 | 2.58 | 10.49 | 65.49 | 20.11 |
| EarningsYield | 0.03 | -0.20 | 0.00 | -0.01 | 0.00 |
After reviewing the key financial ratios for Fervent Synergies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 5. It has increased from -4.28 (Mar 24) to 0.68, marking an increase of 4.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 5. It has increased from -4.28 (Mar 24) to 0.59, marking an increase of 4.87.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 3. It has increased from -4.27 (Mar 24) to 0.68, marking an increase of 4.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.12. It has increased from 10.13 (Mar 24) to 11.12, marking an increase of 0.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.12. It has increased from 10.13 (Mar 24) to 11.12, marking an increase of 0.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.42. It has decreased from 8.10 (Mar 24) to 7.42, marking a decrease of 0.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 2. It has increased from -4.25 (Mar 24) to 0.68, marking an increase of 4.93.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from -4.27 (Mar 24) to 0.67, marking an increase of 4.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from -4.28 (Mar 24) to 0.67, marking an increase of 4.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 2. It has increased from -4.28 (Mar 24) to 0.67, marking an increase of 4.95.
- For PBDIT Margin (%), as of Mar 25, the value is 9.20. This value is below the healthy minimum of 10. It has increased from -52.50 (Mar 24) to 9.20, marking an increase of 61.70.
- For PBIT Margin (%), as of Mar 25, the value is 9.08. This value is below the healthy minimum of 10. It has increased from -52.67 (Mar 24) to 9.08, marking an increase of 61.75.
- For PBT Margin (%), as of Mar 25, the value is 9.08. This value is below the healthy minimum of 10. It has increased from -52.84 (Mar 24) to 9.08, marking an increase of 61.92.
- For Net Profit Margin (%), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from -52.82 (Mar 24) to 9.09, marking an increase of 61.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.07. This value is below the healthy minimum of 15. It has increased from -42.27 (Mar 24) to 6.07, marking an increase of 48.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.05. This value is below the healthy minimum of 10. It has increased from -42.00 (Mar 24) to 6.05, marking an increase of 48.05.
- For Return On Assets (%), as of Mar 25, the value is 6.05. This value is within the healthy range. It has increased from -42.08 (Mar 24) to 6.05, marking an increase of 48.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.65 (Mar 24) to 0.81, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1,166.31. This value exceeds the healthy maximum of 3. It has increased from 795.38 (Mar 24) to 1,166.31, marking an increase of 370.93.
- For Quick Ratio (X), as of Mar 25, the value is 1,166.31. This value exceeds the healthy maximum of 2. It has increased from 795.38 (Mar 24) to 1,166.31, marking an increase of 370.93.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14,935.00. This value is within the healthy range. It has increased from -304.63 (Mar 24) to 14,935.00, marking an increase of 15,239.63.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 14,769.00. This value is within the healthy range. It has increased from -305.48 (Mar 24) to 14,769.00, marking an increase of 15,074.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 96.89. It has increased from 62.69 (Mar 24) to 96.89, marking an increase of 34.20.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For EV / EBITDA (X), as of Mar 25, the value is 32.44. This value exceeds the healthy maximum of 15. It has increased from -4.91 (Mar 24) to 32.44, marking an increase of 37.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 1.99, marking a decrease of 0.07.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -0.20 (Mar 24) to 0.03, marking an increase of 0.23.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fervent Synergies Ltd:
- Net Profit Margin: 9.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.05% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.07% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 14769
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1166.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.5 (Industry average Stock P/E: 46.54)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/7-8, Satyam Shopping Centre, Mumbai Maharashtra 400077 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay P Thakkar | Chairman |
| Mr. Sanjay P Thakkar | Managing Director |
| Mr. Karan Thakkar | Director & CFO |
| Mr. Nitin Parikh | Independent Director |
| Mr. Rajesh Maheshwari | Independent Director |
| Mrs. Falguni Mehta | Independent Director |
FAQ
What is the intrinsic value of Fervent Synergies Ltd?
Fervent Synergies Ltd's intrinsic value (as of 01 February 2026) is ₹19.84 which is 2.27% higher the current market price of ₹19.40, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹96.9 Cr. market cap, FY2025-2026 high/low of ₹29.8/17.0, reserves of ₹4.15 Cr, and liabilities of ₹54.28 Cr.
What is the Market Cap of Fervent Synergies Ltd?
The Market Cap of Fervent Synergies Ltd is 96.9 Cr..
What is the current Stock Price of Fervent Synergies Ltd as on 01 February 2026?
The current stock price of Fervent Synergies Ltd as on 01 February 2026 is ₹19.4.
What is the High / Low of Fervent Synergies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fervent Synergies Ltd stocks is ₹29.8/17.0.
What is the Stock P/E of Fervent Synergies Ltd?
The Stock P/E of Fervent Synergies Ltd is 26.5.
What is the Book Value of Fervent Synergies Ltd?
The Book Value of Fervent Synergies Ltd is 10.8.
What is the Dividend Yield of Fervent Synergies Ltd?
The Dividend Yield of Fervent Synergies Ltd is 0.00 %.
What is the ROCE of Fervent Synergies Ltd?
The ROCE of Fervent Synergies Ltd is 7.47 %.
What is the ROE of Fervent Synergies Ltd?
The ROE of Fervent Synergies Ltd is 7.47 %.
What is the Face Value of Fervent Synergies Ltd?
The Face Value of Fervent Synergies Ltd is 10.0.